Literature DB >> 2406803

Early immune events in scleroderma.

A E Postlethwaite1.   

Abstract

A number of humoral and cellular immune abnormalities are present in patients with early scleroderma (systemic sclerosis). Most of these abnormalities reflect ongoing autoimmune reactions of the cellular and humoral types, resulting in a variety of autoantibodies to cellular and tissue constituents. Evidence exists for a defect(s) in immunoregulation favoring excessive helper T-cell activity. The presence of circulating cytokines and shed interleukin-2 receptors suggest ongoing cellular immune reactions are occurring, generating cytokines and lymphokines that are capable of effecting the vascular and fibrotic lesions that are hallmarks of the disease. Future directions for research are suggested that would focus on determining if, and at what point, fibroblasts might function autonomously to generate excessive matrix components and on determining the nature of the original antigenic stimulus that starts the scleroderma process.

Entities:  

Mesh:

Year:  1990        PMID: 2406803

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  4 in total

Review 1.  How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?

Authors:  O Meyer
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

2.  Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122.

Authors:  A E Postlethwaite; J M Seyer
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

3.  Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis.

Authors:  P P Sfikakis; J Tesar; S Theocharis; G L Klipple; G C Tsokos
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

4.  Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient.

Authors:  Ruby Kochhar; Jay N Umbreit
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.